DeciPHer-ILD: a Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

Description

This is a prospective, non-interventional, multicenter, registry of patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Conditions

Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Pulmonary Hypertension, Interstitial Lung Disease

Talk to us

Study Overview

On this page

Study Details

Study overview

This is a prospective, non-interventional, multicenter, registry of patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD).

DeciPHer-ILD: a Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

DeciPHer-ILD: a Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

Condition
Pulmonary Hypertension Due to Lung Diseases and Hypoxia
Intervention / Treatment

-

Contacts and Locations

Anderson

AnMed Health, Anderson, South Carolina, United States, 29621

Richmond

Pulmonary Associates of Richmond, Inc., Richmond, Virginia, United States, 23230

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Adults aged 18 years or older
  • 2. Diagnosis of ILD by traditional or HRCT determined by the site/institution that conducted the HRCT
  • 3. Patients with connective tissue disease must have a baseline forced vital capacity of \<70%
  • 4. RHC confirmed PH (mean pulmonary artery pressure \>20 mmHg, pulmonary arterial wedge pressure ≤15 mmHg, pulmonary vascular resistance \>2 WU).
  • 5. For patients to be eligible for Cohort 1, they must not be receiving inhaled treprostinil at Baseline.
  • 6. For patients to be eligible for Cohort 2, they must have initiated Tyvaso/Tyvaso DPI at 1 of the following time points:
  • 1. Baseline
  • 2. ≤60 days prior to Baseline
  • 7. For patients to be eligible for Cohort 3, they must be receiving Tyvaso/Tyvaso DPI at Baseline and for \>60 days prior to Baseline
  • 8. Co-enrollment in other observational or interventional studies is permitted
  • 9. Patient is willing and able to provide informed consent and complete surveys/questionnaires in English or Spanish
  • 1. Confirmed diagnosis of Group 1, 2, 4, or 5 PH
  • 2. Confirmed diagnosis of Group 3 PH related to chronic obstructive pulmonary disease or conditions that cause hypoxemia, such as untreated or inadequately treated obstructive sleep apnea and alveolar hypoventilation disorders
  • 3. Patients receiving Yutrepia (inhaled treprostinil) at Baseline.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

United Therapeutics,

Study Record Dates

2030-11-30